117833-18-8

Basic information

• Product Name: AC-ASP(OTBU)-OH
• Synonyms: N-ALPHA-ACETYL-L-ASPARTIC ACID BETA-T-BUTYL ESTER;ACETYL-L-ASPARTIC ACID BETA-T-BUTYL ESTER;AC-ASPARTIC ACID(OTBU)-OH;AC-ASP(OTBU)-OH;N-Acetyl-L-aspartic acid 4-tert-butyl ester;(2S)-2-AcetaMido-4-[(2-Methyl-2-propanyl)oxy]-4-oxobutanoic acid;(S)-2-AcetaMido-4-(tert-butoxy)-4-oxobutanoic acid;Acetyl-L-aspartic acid beta-tert-butyl ester
• CAS NO: 117833-18-8
• Molecular Formula: C₁₀H₁₇NO₅
• Molecular Weight: 231.25
• Mol File: 117833-18-8.mol

Chemical Properties

• Melting Point: 163-164 °C
• Boiling Point: 449.609 °C at 760 mmHg
• Flash Point: 225.716 °C
• Appearance: /Solid
• Density: 1.168 g/cm³
• Storage Temp.: 2-8°C
• PKA: 3.24±0.10(Predicted)
• CAS DataBase Reference: AC-ASP(OTBU)-OH(CAS DataBase Reference)
• NIST Chemistry Reference: AC-ASP(OTBU)-OH(117833-18-8)
• EPA Substance Registry System: AC-ASP(OTBU)-OH(117833-18-8)

Safety Data

• Hazardous Substances Data: 117833-18-8(Hazardous Substances Data)

Usage

Physical Form

A crystalline solid

Uses

AC-Asp(OtBU)-OH is a useful research chemical.

Upstream product

• 71989-14-5 Fmoc-(tBu)Asp-OH 
• 108-24-7 acetic anhydride 
• 3057-74-7 L-Asp(t-Bu) 
• 830-03-5 4-nitrophenol acetate 

Downstream Products

• 863667-42-9 4-(2-acetylamino-3-tert-butoxycarbonyl-propionylamino)-4-{1-[2-tert-butoxycarbonyl-1-(4-nitro-phenylcarbamoyl)-ethylcarbamoyl]-2-methyl-propylcarbamoyl}-butyric acid tert-butyl ester 
• 1599486-24-4 C₄₃H₅₃N₃O₉S 
• 273215-70-6 (3S)-3-((2S)-2-[((2S)-2-[(2S)-2-(Acetylamino)-3-carboxypropanoyl]amino-4-carboxybutanoyl)amino]-3-methylbutanoylamino)-4-oxo-7-phenylheptanoic acid 
• 863667-26-9 3-{2-[2-(2-acetylamino-3-tert-butoxycarbonyl-propionylamino)-4-tert-butoxycarbonyl-butyrylamino]-3-methyl-butyrylamino}-6-(2,5-dimethyl-phenyl)-4-oxo-hexanoic acid tert-butyl ester 
• 863667-25-8 3-{2-[2-(2-acetylamino-3-tert-butoxycarbonyl-propionylamino)-4-tert-butoxycarbonyl-butyrylamino]-3-methyl-butyrylamino}-4-oxo-6-m-tolyl-hexanoic acid tert-butyl ester 
• 863667-24-7 (S)-3-{(S)-2-[(S)-2-((S)-2-Acetylamino-3-tert-butoxycarbonyl-propionylamino)-4-tert-butoxycarbonyl-butyrylamino]-3-methyl-butyrylamino}-4-oxo-7-phenyl-heptanoic acid methyl ester 
• 863667-30-5 (S)-3-{(S)-2-[(S)-2-((S)-2-Acetylamino-3-tert-butoxycarbonyl-propionylamino)-4-tert-butoxycarbonyl-butyrylamino]-3-methyl-butyrylamino}-4-cyclohexyl-4-oxo-butyric acid methyl ester 
• 863667-23-6 (S)-3-{(S)-2-[(S)-2-((S)-2-Acetylamino-3-tert-butoxycarbonyl-propionylamino)-4-tert-butoxycarbonyl-butyrylamino]-3-methyl-butyrylamino}-4-oxo-6-phenyl-hexanoic acid methyl ester 
• 189684-50-2 N-α-acetyl-Asp-Glu-Val-Asp-p-nitroanilide 
• 863667-22-5 (S)-3-{(S)-2-[(S)-2-((S)-2-Acetylamino-3-tert-butoxycarbonyl-propionylamino)-4-tert-butoxycarbonyl-butyrylamino]-3-methyl-butyrylamino}-4-oxo-5-phenyl-pentanoic acid methyl ester 
• 863667-31-6 (S)-3-{(S)-2-[(S)-2-((S)-2-Acetylamino-3-tert-butoxycarbonyl-propionylamino)-4-tert-butoxycarbonyl-butyrylamino]-3-methyl-butyrylamino}-4-oxo-4-phenyl-butyric acid methyl ester 

Relevant articles and documents

VEGF NEUTRALIZING PRODRUGS FOR THE TREATMENT OF OCULAR CONDITIONS

The present invention relates to a pharmaceutical composition comprising one or more pharmaceutically acceptable excipient(s) and a VEGF neutralizing prodrug, which comprises a VEGF neutralizing biologically active moiety, for use in a method for the treatment of one or more ocular conditions.

Using peptidic inhibitors to systematically probe the S1′ site of caspase-3 and caspase-7

(Chemical Equation Presented) Fifteen ketone-containing peptides were designed, synthesized, and used to probe the effect of substitution at the P1′ position on caspase-3 and -7 inhibition. Even with the large bias of Ac-Asp-Glu-Val-Asp at the P4-P1 positions, certain peptides with cyclic functionality in the P1′ position show a dramatically reduced ability to inhibit these caspases. Additionally, trends toward isozyme selectivity were also uncovered for particular P1′ substituents. The data indicate that substitution in the P1′ position can drastically affect both caspase inhibition and selectivity.

N-acetylaspartylglutamic acid and its β-isomer

The α-isomer is predominantly formed in the synthesis of N-acetylaspartylglutamic acid and its β-isomer upon cleavage of N-acetylaspartic acid anhydride by the diethyl ester of glutamic acid.